Evidence map›Paper›PMID 39580584›Full record

ArticleLeukemia2025

High CD44 expression and enhanced E-selectin binding identified as biomarkers of chemoresistant leukemic cells in human T-ALL.

Julien Calvo, Irina Naguibneva, Anthony Kypraios, Florian Gilain, Benjamin Uzan, Baptiste Gaillard, Lea Bellenger, Laurent Renou, Christophe Antoniewski, Helene Lapillonne and 6 more

Abstract read
In one paragraph

Article in Leukemia, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Julien CalvoUniversité Paris Cité, Inserm, CEA, Stabilité Génétique Cellules Souches et Radiations, iRCM/SGCSR/Laboratoire des cellules Souches Hématopoïétiques et des Leucémies (LSHL), F-92260, Fontenay-aux-Roses, France. julien.calvo@cea.fr.ORCID http://orcid.org/0000-0003-1316-4306
Irina Naguibneva *Université Paris Cité, Inserm, CEA, Stabilité Génétique Cellules Souches et Radiations, iRCM/SGCSR/Laboratoire des cellules Souches Hématopoïétiques et des Leucémies (LSHL), F-92260, Fontenay-aux-Roses, France.
Anthony Kypraios *Université Côte d'Azur, Centre Méditerranéen de Médecine Moléculaire (C3M), INSERM U1065, 06204, Nice, France.
Florian Gilain *Université Paris Cité, Inserm, CEA, Stabilité Génétique Cellules Souches et Radiations, iRCM/SGCSR/Laboratoire des cellules Souches Hématopoïétiques et des Leucémies (LSHL), F-92260, Fontenay-aux-Roses, France.
Benjamin UzanUniversité Paris Cité, Inserm, CEA, Stabilité Génétique Cellules Souches et Radiations, iRCM/SGCSR/Laboratoire des cellules Souches Hématopoïétiques et des Leucémies (LSHL), F-92260, Fontenay-aux-Roses, France.
Baptiste GaillardUniversité Paris Cité, Inserm, CEA, Stabilité Génétique Cellules Souches et Radiations, iRCM/SGCSR/Laboratoire des cellules Souches Hématopoïétiques et des Leucémies (LSHL), F-92260, Fontenay-aux-Roses, France.
Lea BellengerARTbio Bioinformatics Analysis Facility, IBPS, CNRS, Sorbonne Université, Institut Français de Bioinformatique, 75005, Paris, France.
Laurent RenouUniversité Paris Cité, Inserm, CEA, Stabilité Génétique Cellules Souches et Radiations, iRCM/SGCSR/Laboratoire des cellules Souches Hématopoïétiques et des Leucémies (LSHL), F-92260, Fontenay-aux-Roses, France.
Christophe AntoniewskiARTbio Bioinformatics Analysis Facility, IBPS, CNRS, Sorbonne Université, Institut Français de Bioinformatique, 75005, Paris, France.
Helene LapillonneSorbonne University, AP-HP, Laboratory of Hematology, Armand-Trousseau Hospital, 75012, Paris, France.
Arnaud PetitSorbonne University, AP-HP, Laboratory of Hematology, Armand-Trousseau Hospital, 75012, Paris, France.ORCID http://orcid.org/0000-0001-8363-1622
Paola BalleriniSorbonne University, AP-HP, Laboratory of Hematology, Armand-Trousseau Hospital, 75012, Paris, France.
Stéphane Jc ManciniUniversité Rennes, EFS, Inserm, MOBIDIC-UMR_S 1236, F-35000, Rennes, France.ORCID http://orcid.org/0000-0001-9255-4606
Tony MarchandUniversité Rennes, EFS, Inserm, MOBIDIC-UMR_S 1236, F-35000, Rennes, France.
Jean-François PeyronUniversité Côte d'Azur, Centre Méditerranéen de Médecine Moléculaire (C3M), INSERM U1065, 06204, Nice, France.ORCID http://orcid.org/0000-0001-6113-916X
Françoise PflumioUniversité Paris Cité, Inserm, CEA, Stabilité Génétique Cellules Souches et Radiations, iRCM/SGCSR/Laboratoire des cellules Souches Hématopoïétiques et des Leucémies (LSHL), F-92260, Fontenay-aux-Roses, France.ORCID http://orcid.org/0000-0001-8995-596X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

T-cell acute lymphoblastic leukemia (T-ALL) is a hematopoietic malignancy characterized by increased proliferation and incomplete maturation of T-cell progenitors, for which relapse is often of poor prognosis. To improve patient outcomes, it is critical to understand the chemoresistance mechanisms arising from cell plasticity induced by the bone marrow (BM) microenvironment. Single-cell RNA sequencing of human T-ALL cells from adipocyte-rich and adipocyte-poor BM revealed a distinct leukemic cell population defined by quiescence and high CD44 expression (Ki67

Indexed as

Biomarkers, TumorDrug Resistance, NeoplasmE-SelectinHyaluronan ReceptorsPrecursor T-Cell Lymphoblastic Leukemia-LymphomaHumansPrognosisTumor MicroenvironmentBiomarkers, TumorCD44 protein, humanE-SelectinHyaluronan Receptors

Identifiers

PMID39580584
PMCPMC11794132

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.